USE OF FGFR INHIBITORS IN FGFR-GENETICALLY ALTERED CANCERS TO ENHANCE PATIENT RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SEQUENTIAL TREATMENT SETTINGS

USE OF FGFR INHIBITORS IN FGFR-GENETICALLY ALTERED CANCERS TO ENHANCE PATIENT RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SEQUENTIAL TREATMENT SETTINGS

Embodiments of the present invention relate to a method of treating cancer in a patient comprising administering an immune checkpoint inhibitor to the patient, wherein the patient has been diagnosed with an FGFR-genetically altered cancer, and has been pre-treated with an FGFR inhibitor, such as erd...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ZUDAIRE, Enrique, SANTIAGO-WALKER, Ademi, Elena, VERONA, Raluca, SHALABY, Waleed, S
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Embodiments of the present invention relate to a method of treating cancer in a patient comprising administering an immune checkpoint inhibitor to the patient, wherein the patient has been diagnosed with an FGFR-genetically altered cancer, and has been pre-treated with an FGFR inhibitor, such as erdafitinib.